Rabbit Recombinant Monoclonal CXCL5 antibody. Carrier free. Suitable for IP, WB, IHC-P and reacts with Human, Recombinant fragment - Human samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
IP | WB | IHC-P | |
---|---|---|---|
Human | Tested | Tested | Tested |
Recombinant fragment - Human | Not recommended | Tested | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Recombinant fragment - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - Human | Dilution info - | Notes - |
Involved in neutrophil activation. In vitro, ENA-78(8-78) and ENA-78(9-78) show a threefold higher chemotactic activity for neutrophil granulocytes.
CXCL6
ENA78, SCYB5, CXCL5, C-X-C motif chemokine 5, ENA-78(1-78), Epithelial-derived neutrophil-activating protein 78, Neutrophil-activating peptide ENA-78, Small-inducible cytokine B5
Rabbit Recombinant Monoclonal CXCL5 antibody. Carrier free. Suitable for IP, WB, IHC-P and reacts with Human, Recombinant fragment - Human samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
ab284855 is the carrier-free version of Anti-CXCL5 + CXCL6 antibody [EP13083] ab198505
The production method for this product has been changed from hybridoma to recombinant on 15th April 2024.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
C-X-C motif chemokine ligands 5 and 6 (CXCL5 and CXCL6) also known as ENA-78 and GCP-2 respectively are small proteins with a molecular mass of approximately 12 kDa. These chemokines belong to the CXC chemokine family and play key roles as signaling proteins. CXCL5 and CXCL6 are mainly expressed in neutrophils epithelial cells and to some extent in macrophages. When they bind to their receptor CXCR2 they induce chemotaxis guiding immune cells toward sites of inflammation or injury.
They coordinate immune response by mediating neutrophil recruitment to inflammatory sites. CXCL5 and CXCL6 often work as a team binding CXCR2 and aiding in protective tissue responses. Their roles extend further as they partake in triggering angiogenesis the formation of new blood vessels under physiological or pathological conditions such as wound healing or cancer. These activities imply their involvement in complex cellular networks and interactions.
The involvement of CXCL5 and CXCL6 arises prominently in the NF-kB pathway and the MAPK signaling pathway. These pathways integral to immune and inflammatory responses reflect the chemokines' interaction with proteins like IL-8 and TNF-alpha emphasizing their importance in host defense mechanisms and inflammatory signaling cascades. Their ability to engage with these pathways demonstrates an essential role in modulating the intensity and duration of inflammatory responses.
CXCL5 and CXCL6 relate to conditions such as cancer and rheumatoid arthritis. In cancer these chemokines can enhance tumor progression by increasing angiogenesis and attracting cells that promote tumor growth. Similarly in rheumatoid arthritis their overexpression correlates with joint inflammation and tissue damage. Proteins like VEGF-A connected to these chemokines further underline their association with pathological angiogenesis and inflammatory process regulation in disease states.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-CXCL5 + CXCL6 antibody [EP13083] ab198505, the same antibody clone in a different buffer formulation.
CXCL5 + CXCL6 was immunoprecipitated from 0.35 mg of A549 (Human lung carcinoma cell line) whole cell extract with Anti-CXCL5 + CXCL6 antibody [EP13083] ab198505 at 1/30 dilution. Western blot was performed from the immunoprecipitate using Anti-CXCL5 + CXCL6 antibody [EP13083] ab198505 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366), was used as secondary antibody at 1/5000 dilution.
Lane 1: A549 (Human lung carcinoma epithelial cell), whole cell lysate, 10µg
Lane 2: A549 whole cell lysate with the Anti-CXCL5 + CXCL6 antibody [EP13083] ab198505 at 1/30 dilution
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of Anti-CXCL5 + CXCL6 antibody [EP13083] ab198505 in A549 whole cell lysate
All lanes: Immunoprecipitation - Anti-CXCL5 + CXCL6 antibody [EP13083] (Anti-CXCL5 + CXCL6 antibody [EP13083] ab198505) at 1/1000 dilution
All lanes: A549 (Human lung carcinoma epithelial cell), whole cell lysate
All lanes: Immunoprecipitation - VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) at 1/5000 dilution
Predicted band size: 12 kDa
Exposure time: 93s
This data was developed using Anti-CXCL5 + CXCL6 antibody [EP13083] ab198505, the same antibody clone in a different buffer formulation.
The expression of CXCL5 and CXCL6 is induced by TNF-a and PMA. (PMID 9057843; PMID: 23922745).
Anti-GAPDH antibody [EPR16891] - Loading Control ab181602 was used a GAPDH loading control.
All lanes: Western blot - Anti-CXCL5 + CXCL6 antibody [EP13083] (Anti-CXCL5 + CXCL6 antibody [EP13083] ab198505) at 1/10000 dilution
Lane 1: HEK-293T cells transfected with an empty expression vector containing His tag, hole cell lysate with 5% NFDM/TBST
Lane 2: HEK-293T cells transfected with a human CXCL5 expression vector containing His tag, then treated with 600 ng/ml BFA for 3h, whole cell lysate with 5% NFDM/TBST
Lane 3: HEK-293T cells transfected with a human CXCL6 expression vector containing His tag, then treated with 600 ng/ml BFA for 3h, whole cell lysate with 5% NFDM/TBST
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 12 kDa
Exposure time: 10s
This data was developed using Anti-CXCL5 + CXCL6 antibody [EP13083] ab198505, the same antibody clone in a different buffer formulation.
The expression of CXCL5 and CXCL6 is induced by TNF-a and PMA. (PMID 9057843; PMID: 23922745).
Anti-GAPDH antibody [EPR16891] - Loading Control ab181602 was used a GAPDH loading control.
All lanes: Western blot - Anti-CXCL5 + CXCL6 antibody [EP13083] (Anti-CXCL5 + CXCL6 antibody [EP13083] ab198505) at 1/10000 dilution
Lane 1: A549 (Human lung carcinoma epithelial cell) starved overnight, whole cell lysate at 15 µg with 5% NFDM/TBST
Lane 2: A549 (Human lung carcinoma epithelial cell) starved overnight, then treated with 10ng/ml TNF-a, 10nM TPA and 0.1% BSA for 24 hours, whole cell lysate at 15 µg with 5% NFDM/TBST
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 12 kDa
Exposure time: 10s
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com